Skip to content
Screener

Maze Therapeutics MAZE Book value per share

Book value per share at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$79.34+19.6%
Septerna, Inc. logo
Septerna, Inc.SEPN
$8.59+0.4%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$6.26+6.2%
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
$4.67+4.1%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$3.62-32.1%
Schrodinger logo
SchrodingerSDGR
$4.34-7.0%

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$48.0M-31.7%
Net income-$44.7M-32.8%
EPS (diluted)-$0.76+1.3%

Balance sheet

See full
Cash & equivalents$202.6M-23.4%
Total debt$60.4M+142%
Total equity$453.1M+72.8%
Total assets$531.6M+75.2%

Cash flow

See full
Operating cash flow-$15.1M+49.9%
CapEx$107.0K-72.8%
Free cash flow-$15.2M+50.2%

Valuation

See full
Market cap$1.51B+156%
Enterprise value$1.37B+290%

Returns & leverage

See full
Return on equity-37.3%
Debt / equity0.1×0.0×
Current ratio18.3×+4.7×

Where this comes from

Calculated from Maze Therapeutics’s reported figures.

Based on the most recent quarter.

The source filing: Maze Therapeutics’s 10-Q, filed August 11, 2026. Open the filing →

Filed
Aug 11, 2026, 4:48 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-344903

FAQ

What is Maze Therapeutics's book value per share?
Maze Therapeutics (MAZE) reported book value per share of $7.68 in Q2 2026.
How has Maze Therapeutics's book value per share changed year-over-year?
Maze Therapeutics's book value per share increased by 28.3% year-over-year, from $5.99 to $7.68.
What does book value per share mean?
Shareholders' equity divided by diluted shares outstanding at the quarter end. The accounting (book) value attributable to each share.

Ask your AI about Maze Therapeutics's book value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude